Takeda in ADHD

For more than two decades Takeda, previously Shire, has demonstrated leadership in neuroscience through helping more patients, advancing our pipeline, and expanding into additional conditions. Misunderstanding of conditions like attention-deficit hyperactivity disorder (ADHD) is widespread, which can add to the unique challenges people living with this condition face. Building awareness and understanding can remove some of the additional obstacles these people may encounter.

We’ve built relationships with patient advocacy groups and organisations globally, and regularly share our expertise with physicians, patients, caregivers, and policymakers to raise awareness and broaden understanding of these conditions worldwide. We are also committed to helping combat the misuse, abuse and diversion of ADHD medicines.

Date of preparation: March 2023; Job code: C-ANPROM/EUC/NBU/0008